<SEC-DOCUMENT>0001628280-26-001898.txt : 20260112
<SEC-HEADER>0001628280-26-001898.hdr.sgml : 20260112
<ACCEPTANCE-DATETIME>20260112185252
ACCESSION NUMBER:		0001628280-26-001898
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260108
FILED AS OF DATE:		20260112
DATE AS OF CHANGE:		20260112

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Zuga Matt
		CENTRAL INDEX KEY:			0001790214
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40551
		FILM NUMBER:		26528071

	MAIL ADDRESS:	
		STREET 1:		C/O TELA BIO, INC.
		STREET 2:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acumen Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001576885
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				364108129
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1210-1220 WASHINGTON STREET
		STREET 2:		SUITE 210
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02465
		BUSINESS PHONE:		617-344-4190

	MAIL ADDRESS:	
		STREET 1:		1210-1220 WASHINGTON STREET
		STREET 2:		SUITE 210
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02465
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1768261959.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-01-08</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001576885</issuerCik>
        <issuerName>Acumen Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>ABOS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001790214</rptOwnerCik>
            <rptOwnerName>Zuga Matt</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ACUMEN PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1210-1220 WASHINGTON STREET, SUITE 210</rptOwnerStreet2>
            <rptOwnerCity>NEWTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02465</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>CFO &amp; Chief Business Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2026-01-08</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>6888</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.8166</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>209951</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">Represents the number of shares sold by the Reporting Person through an automatic &quot;sell to cover&quot; transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025.</footnote>
        <footnote id="F2">The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Derek Meisner, Attorney-in-Fact</signatureName>
        <signatureDate>2026-01-12</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
